利妥昔单抗治疗后视神经脊髓炎迅速加重。
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
作者信息
Dai Yongqiang, Lu Tingting, Wang Yuge, Fang Ling, Li Rui, Kermode Allan G, Qiu Wei
机构信息
Department of Neurology, Third Affiliated Hospital of Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou 510275, China.
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Department of Neurology, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, WA, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, WA, Australia.
出版信息
J Clin Neurosci. 2016 Apr;26:168-70. doi: 10.1016/j.jocn.2015.08.033. Epub 2015 Dec 15.
Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.
研究表明免疫抑制剂对视神经脊髓炎（NMO）有效。利妥昔单抗被推荐作为治疗难治性NMO的非适应证用药。然而，我们描述了两名对利妥昔单抗反应欠佳且治疗后症状加重的此类患者。我们的警示性病例突出表明，在一小部分难治性NMO患者中，利妥昔单抗可能无效或导致NMO迅速复发。这表明我们需要考虑为难治性NMO制定新的治疗策略。
Zotero 插件